Announcing the launch of CRISPR Cures for Cancer, a tri-institutional initiative between UCSF, Gladstone Institutes, and the Innovative Genomics Institute at UC Berkeley, which aims to accelerate cell therapy design and development using genomic technologies.
CRISPR Cures for Cancer Initiative is headed by Alex Marson, MD, PhD, Alan Ashworth, PhD, FRS, and Jennifer Doudna, PhD, and is comprised of 20+ investigators across the three institutions who are conducting research at the intersection of genomic technologies and cellular immunotherapies.
Related news:
- Giving Immunotherapy Cells Resilience to Pass the ‘Stress Test’ (UCSF.edu 8/22)
- A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors (UCSF.edu 8/22)
- New CRISPR Technology Offers Unrivaled Control of Epigenetic Inheritance (UCSF.edu 4/21)
“We are so excited to be launching the CRISPR Cures for Cancer Initiative to catalyze transformative new collaborations in the field of genomic immunology,” said Marson, Director of the Gladstone-UCSF Institute of Genomic Immunology. “The potential for real impact on patients from the innovations this group is making in immune cell therapies is astounding.”
By directly funding investigators, collaborative projects, and technology platforms, CRISPR Cures for Cancer will fuel integration of research and discovery with therapeutic process development and clinical trials and is designed to rapidly move innovations to clinical translation after discoveries are made.